Divi Laboratories Q3 Results: The company’s operational performance showed weakness, with its earnings before interest, taxes, depreciation, and amortization (EBITDA) reaching Rs 479 crore, marking an increase of approximately 19.6% from Rs 409 crore. Divi’s Laboratories witnessed a 17 percent year-on-year (YoY) increase in its consolidated profit to Rs 358 crore for the December quarter. Revenue also saw growth, reaching Rs 1,855 crore, marking an 8.6 percent rise from the year-ago quarter’s figure of Rs 1,708 crore.
In the corresponding period last year, the company recorded a profit of Rs 306 crore.
When the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) increased to Rs 479 crore from Rs 409 crore, a 19.6% increase, operational performance was subpar. Additionally, the EBITDA margin increased from 24 percent in the base period to 26.4%. – Divi Laboratories Q3 Results
In the current 9-month period, the forex gain totaled Rs 32 crore, compared to Rs 134 crore in the preceding 9-month period. The company’s board has given approval for the reappointment of Sunaina Singh as an Independent Director for an additional five-year term, starting from March 28, 2024. Additionally, the board has sanctioned the appointment of Devendra Rao as an Additional Director, designated as ‘Whole-time Director (Manufacturing),’ for a term of 5 years beginning February 10.
On Friday, shares of Divi’s Laboratories concluded 0.9% higher at Rs 3,651 each on the BSE, outperforming the benchmark Sensex which saw a modest 0.23% increase.
